Shanghai Runda Medical Technology 배당금
배당금 기준 확인 2/6
Shanghai Runda Medical Technology is a dividend paying company with a current yield of 0.57%.
주요 정보
0.6%
배당 수익률
-0.2%
환매 수익률
| 총 주주 수익률 | 0.4% |
| 미래 배당 수익률 | n/a |
| 배당금 성장 | 10.1% |
| 다음 배당금 지급일 | n/a |
| 전 배당일 | n/a |
| 주당 배당금 | CN¥0.100 |
| 지급 비율 | 154% |
최근 배당금 업데이트
업데이트 없음
Recent updates
Earnings Tell The Story For Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) As Its Stock Soars 39%
Oct 22
These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively
Oct 18Shanghai Runda Medical Technology (SHSE:603108) Has A Somewhat Strained Balance Sheet
Jun 26Shanghai Runda Medical Technology Co., Ltd.'s (SHSE:603108) Earnings Haven't Escaped The Attention Of Investors
Jun 04Does Shanghai Runda Medical Technology (SHSE:603108) Deserve A Spot On Your Watchlist?
Mar 21Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) Stock Rockets 31% But Many Are Still Ignoring The Company
Mar 04These 4 Measures Indicate That Shanghai Runda Medical Technology (SHSE:603108) Is Using Debt Extensively
Feb 27결제의 안정성과 성장
배당금 데이터 가져오기
안정적인 배당: 603108 has been paying a dividend for less than 10 years and during this time payments have been volatile.
배당금 증가: 603108's dividend payments have increased, but the company has only paid a dividend for 8 years.
시장 대비 배당 수익률
| Shanghai Runda Medical Technology 시장 대비 배당 수익률 |
|---|
| 세그먼트 | 배당 수익률 |
|---|---|
| 회사 (603108) | 0.6% |
| 시장 하위 25% (CN) | 0.6% |
| 시장 상위 25% (CN) | 2.2% |
| 업계 평균 (Life Sciences) | 1.2% |
| 애널리스트 예측 (603108) (최대 3년) | n/a |
주목할만한 배당금: 603108's dividend (0.57%) is higher than the bottom 25% of dividend payers in the CN market (0.57%).
고배당: 603108's dividend (0.57%) is low compared to the top 25% of dividend payers in the CN market (2.22%).
주주에 대한 수익 배당금
수익 보장: With its high payout ratio (154.1%), 603108's dividend payments are not well covered by earnings.
주주에 대한 현금 배당금
현금 흐름 범위: With its low cash payout ratio (13.1%), 603108's dividend payments are thoroughly covered by cash flows.